ANDA 202244, held by Apotex Inc. Rizatriptan Benzoate.
As of Nov 14, 2026, ANDA 202244 (Rizatriptan Benzoate), held by Apotex Inc, was first approved by FDA on Dec 31, 2012, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 31, 2012 | Original application | Approved | None posted |
| Rizatriptan BenzoateEQ 5MG BASE · tablet;oral | Rizatriptan Benzoate | Discontinued |
| Rizatriptan BenzoateEQ 10MG BASE · tablet;oral | Rizatriptan Benzoate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
